Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the pheochromocytoma market size evolved in recent years?

The pheochromocytoma market has experienced steady growth in recent years and is projected to increase from $3.03 billion in 2024 to $3.17 billion in 2025, reflecting a CAGR of 4.7%. The historical growth can be attributed to rising healthcare expenditure, increased diagnosis and awareness, advancements in genetic research, and government initiatives.

What are the predictions for the pheochromocytoma market size in the coming years?

The pheochromocytoma market is expected to see steady growth, reaching $3.74 billion in 2029 at a CAGR of 4.2%. Growth is driven by demand for combination therapies, investment in R&D, minimally invasive treatment options, and increased rare disease research initiatives. Trends include a rising number of clinical trials, improved diagnostic and treatment options, gene therapy developments, and advancements in medical imaging.

Get your pheochromocytoma market report here!

https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report

What key factors are fueling the growth of the pheochromocytoma market?

The anticipated growth in the pheochromocytoma market is spurred by the increasing incidence of tumors. Tumors, which can be either benign (non-cancerous) or malignant (cancerous), are abnormal cell growths. The upsurge in cases of tumors and cancer signifies the necessity for heightened medical consciousness, precise diagnoses, and personalized treatment methods to effectively manage desmoid pheochromocytoma. As an example, the American Cancer Society stated in January 2023 that cancer cases increased by 3.16% from 1,898,160 in 2021 to 1,958,310 in 2023. Consequently, the pheochromocytoma market will likely see an upward trend due to the increasing frequency of tumor incidents. An increase in neuroendocrine diseases drives the pheochromocytoma market, propelling its growth. Neuroendocrine diseases, which affect the neuroendocrine network that produces and regulates hormones, are increasing, thus heightening the need for specialized diagnostics, treatment options, surgeries, pharmaceuticals, and patient support systems specific to pheochromocytomas. For instance, March 2023 data from the American Society of Clinical Oncology (ASCO), showed an estimated annual incidence of neuroendocrine diseases like pheochromocytoma to be between 2 to 8 cases per million people, with nearly 15% reported as being cancerous. The projected survival rate for recurrent or metastatic pheochromocytoma over five years is thought to be between 34% and 60%. Thus, the increasing prevalence of neuroendocrine diseases is likely to boost the pheochromocytoma market growth.

How is the global pheochromocytoma market divided into key segments?

The pheochromocytoma market covered in this report is segmented –

1) By Type: Adrenal Pheochromocytoma, Extra-Adrenal Pheochromocytoma

2) By Treatment: Medication, Surgery, Radionuclide Treatment, Other Treatments

3) By Diagnosis: Laboratory Tests, Imaging Tests, Genetic Testing

4) By End Users: Hospitals, Clinics, Research And Academic Institutes, Other End Users

Subsegments:

1) By Adrenal Pheochromocytoma: Unilateral Adrenal Pheochromocytoma, Bilateral Adrenal Pheochromocytoma

2) By Extra-Adrenal Pheochromocytoma: Paraganglioma, Paraganglioma, Paraganglioma

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12909&type=smp

Who are the key firms paving the way for growth in the pheochromocytoma market?

Major companies operating in the pheochromocytoma market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., Teva Pharmaceutical Company Limited, Mylan N.V., Bausch Health Companies Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Apotex Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Endo International PLC, Exelixis Inc., Lupin Limited, Lantheus Holdings Inc., Curium Pharma, ANI Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., WellSpring Pharmaceutical Corporation, HRA Pharma SE.

Which trends are expected to transform the pheochromocytoma market?

Key players in the pheochromocytoma market are engaging in clinical research to discover new treatment methods, therapies, and drugs for pheochromocytoma, contributing to the creation of increasingly efficient and targeted treatments, and enhancing patient results. For example, Novartis AG, a pharmaceutical firm based in Switzerland, initiated Phase 2 of a multicenter open-label study in August 2022 to evaluate the safety and dosimetry of Lutathera in adolescents aged between 12 and less than 18 with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and pheochromocytoma and paragangliomas (PPGL). The study comprises a multicenter, open-label, single-arm design, which includes an exploratory PPGL cohort intended to encompass as many adolescents with PPGL as possible.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12909

What regions are contributing significantly to the growth of the pheochromocytoma market?

North America was the largest region in the pheochromocytoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pheochromocytoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Brain Tumor Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Solid Tumor Cancer Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: